Stockwinners Market Radar for July 22, 2018 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:25 EDT On The Fly: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Syntel (SYNT) announced that it has entered into a definitive merger agreement with Atos S.E. under which Atos will acquire all outstanding shares of Syntel for $41 per share in an all-cash transaction valued at approximately $3.57B, including Syntel's net debt. In connection with the merger agreement, Syntel's founders and certain of their affiliated entities, who collectively own approximately 51.07% of the outstanding Syntel shares, entered into an agreement with Atos to vote their shares in favor of the merger agreement, subject to their right to terminate their obligations in the event the Syntel Board changes its recommendation to shareholders or if the definitive agreement is terminated. The parties expect to close the transaction during the second half of 2018. 2. Fiat Chrysler (FCAU) has named Mike Manley, the head of the carmaker's profit engine Jeep, as its new chief executive, replacing Sergio Marchionne who had to step down after serious complications from surgery. Additionally, the Board of Directors of Ferrari (RACE) said it will propose to shareholders, at a meeting to be called in the coming days, that Louis Camilleri be named CEO as Marchionne steps down. Camilleri is a former Philip Morris (PM) chairman and a member of Ferrari's board. 3. Since the Great Recession, amid ultralow borrowing rates, Amazon (AMZN), Netflix (NFLX), and Tesla (TSLA) have plowed $93B into property and equipment or acquiring video content, amassing $44B of long-term debt, Tiernan Ray wrote in this week's edition of Barron's. It has done wonders for the trio's shares, but while the cooling of credit markets may not imperil their business, it could temper enthusiasm for their stocks, he noted. A possible byproduct of the cooling of borrowing could be investors' return to smaller names in tech that have clean balance sheets and are developing fundamental technologies, the report added. 4. Sony's (SNE) "The Equalizer 2" came in ahead of expectations with an estimated $35.8M launch in North America. The first sequel of Denzel Washington's career, the movie only debuted in 11 markets internationally, earning $3.3M. "The Equalizer 2" earned an A CinemaScore and sports a 50% Rotten Tomatoes score. 5. AllianceBernstein (AB), BlackRock (BLK), Franklin Resources (BEN), Invesco (IVZ), Legg Mason (LM) and T. Rowe Price (TROW) saw positive mentions in Barron's.

16:43 EDT BeiGene planning to pursue accelerated approval in U.S. of Zanubrutinib in WM - BeiGene announced that its investigational BTK inhibitor zanubrutinib has been granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of patients with Waldenstrom macroglobulinemia, or WM. Based on BeiGene's discussions with the FDA, internal review of available data from its global Phase 1 trial of zanubrutinib in patients with WM, and supported by the Fast Track Designation, BeiGene is preparing to submit in the first half of 2019 a New Drug Application to pursue an accelerated approval of zanubrutinib for patients with WM based on results from the global Phase 1 study. A final determination to submit the NDA will be made subsequent to the pre-NDA meeting with FDA after obtaining mature data from the study this fall. In addition to the global Phase 1 trial of zanubrutinib, which enrolled 76 WM patients to date, zanubrutinib is also being tested in a global Phase 3 clinical trial in patients with WM comparing zanubrutinib to ibrutinib, a currently approved BTK inhibitor. BeiGene announced that this global Phase 3 study has completed patient enrollment. In addition, zanubrutinib is being tested in a global Phase 3 clinical trial as a first-line treatment for patients with chronic lymphocytic leukemia and a Phase 2 clinical trial in patients with relapsed or refractory follicular lymphoma in combination with GAZYVA. In China, BeiGene has completed enrollment in three pivotal Phase 2 clinical trials of zanubrutinib in patients with mantle cell lymphoma, CLL and WM, and expects to file an NDA in China for MCL this year. BeiGene is also planning a Phase 3 trial for a head-to-head comparison of zanubrutinib versus ibrutinib in patients with relapsed/refractory CLL/small lymphocytic lymphoma. As of May 7, 2018, more than 1,200 patients have been enrolled in the zanubrutinib development program.

16:13 EDT Syntel enters definitive agreement to be acquired by Atos S.E. - Syntel announced that it has entered into a definitive merger agreement with Atos S.E. under which Atos will acquire all outstanding shares of Syntel for $41 per share in an all-cash transaction valued at approximately $3.57B, including Syntel's net debt. The transaction was unanimously approved by the full Board of Directors of Syntel based on the unanimous recommendation of a Special Committee of the Board. Completion of this transaction is subject to regulatory approvals, approval of Syntel's shareholders and other customary closing conditions. Completion of this transaction is not subject to any financing condition. In connection with the merger agreement, Syntel's founders and certain of their affiliated entities, who collectively own approximately 51.07% of the outstanding Syntel shares, entered into an agreement with Atos to vote their shares in favor of the merger agreement, subject to their right to terminate their obligations in the event the Syntel Board changes its recommendation to shareholders or if the definitive agreement is terminated. The parties expect to close the transaction during the second half of 2018.

12:11 EDT KKR consortium proposes acquisition of LCY Chemical - LCY Chemical and global investment firm KKR announced the signing of a share exchange agreement for a consortium led by KKR to acquire all of the issued and outstanding shares of LCY for TWD56 per share in cash, adjusted to include a TWD2.90 per share dividend. The transaction, which has been unanimously approved by the board of directors of LCY upon the recommendation of its Audit Committee comprising independent directors, represents a total market capitalization of approximately $1.56B. The offer price represents a premium of 17.28% to LCY's closing price on 20 July 2018, the last trading day prior to the transaction announcement. It also represents a premium of 19.2%, 23.0% and 24.3% over the 30-day, 90-day and 180-day average closing prices, respectively. Immediately following consummation of the share swap, KKR will hold a majority and controlling interest in LCY. KKR makes its proposed investment from its Asian Fund III. The transaction is expected to close in the fourth quarter of 2018, subject to customary closing conditions and regulatory approvals. Upon the completion of the transaction, LCY will become a private company, and its shares will no longer be traded on the Taiwan Stock Exchange.

11:55 EDT Mondelez conducts voluntary recall of certain Ritz Cracker sandwiches - Mondelez Global announced a voluntary recall in the U.S., including Puerto Rico and the U.S. Virgin Islands, of certain Ritz Cracker Sandwiches and Ritz Bits product. These products contain whey powder as an ingredient, which the whey powder supplier has recalled due to the potential presence of Salmonella. There have been no complaints of illness reported to Mondelez Global to date in connection with these products. The company is conducting this recall as a precaution, based on the ingredient supplier's recall.